Hubei Hongyuan Pharmaceutical Technology301246.SZValuation Analysis

As of Oct 19, 2026, Hubei Hongyuan Pharmaceutical Technology (301246.SZ) trades at a P/E of 22.70x, P/B of 1.39x, P/S of 2.37x, and a dividend yield of 0.31%.
Longitudinal percentile comparison: P/E sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 32nd percentile over the trailing 10Y window (vs. 38th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 28th percentile within its industry and the 30th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.54%, ranking at the 75th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 30.8 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 0.54% total shareholder yield, 0.31% is paid out as dividends and roughly 0.23% is implied to come from buybacks — both channels are meaningfully in play. Hubei Hongyuan Pharmaceutical Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.